The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kalinin M.N.
Kazan State Medical University;
Interregional Clinical Diagnostic Center
Khasanova D.R.
Kazan State Medical University;
Interregional Clinical Diagnostic Center
Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3‑2): 77‑93
Views: 529
Downloaded: 15
To cite this article:
Kalinin MN, Khasanova DR. Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry.
2025;125(3‑2):77‑93. (In Russ.)
https://doi.org/10.17116/jnevro202512503277
To evaluate the effect of Cerebrolysin on hazard dynamics of hemorrhagic transformation (HT) and identify optimal anticoagulation therapy (AT) resumption timing in stroke patients, stratified by the Hemorrhagic Transformation Index (HTI).
A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions. The intervention group (IG, n=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, n=147) received IVT and standard care alone. Additionally, a validation cohort (VC, n=248) from an observational study was analyzed. Patients were stratified into low-risk (HT=0), high-risk (HTI=1—4), and very-high-risk (HTI=5—8, VC only) groups. Symptomatic HT and any HT within 14 days post-stroke were defined as failure events. Hazard dynamics were modeled using a Gompertz parametric survival approach, with a hazard threshold (0.6% per day) estimating safe AT resumption timing.
Cerebrolysin significantly reduced risk of symptomatic HT (HR 0.245; 95% CI 0.072—0.837; p=0.02) and any HT (HR 0.543; 95% CI 0.297—0.991; p=0.032). The compounding effect peaked on day 1 and persisted through days 7—10 in very-high-risk patients (HTI=5—8). In high-risk patients (HTI=1—4), Cerebrolysin mitigated the compounding effect and reduced hazard levels to the threshold by day 2, compared to days 3—5 in the CG and VC. The hazardous period extended to day 10 in HTI=5—8. In low-risk patients (HTI=0), hazard levels remained below the threshold from day 1, with no measurable impact of Cerebrolysin on HT.
AT may be safely resumed within 48 h in low-risk patients (HTI=0), on days 3—5 in high-risk patients (HTI=1—4), and on day 10 in very-high-risk patients (HTI=5—8) without symptomatic HT. Cerebrolysin mitigates the compounding effect, reduces HT risk, and facilitates earlier, safer AT resumption in high-risk patients (HTI=1—4) by day 2 post-stroke, supporting its role in personalized stroke management.
Keywords:
Authors:
Kalinin M.N.
Kazan State Medical University;
Interregional Clinical Diagnostic Center
Khasanova D.R.
Kazan State Medical University;
Interregional Clinical Diagnostic Center
Received:
10.01.2025
Accepted:
13.01.2025
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.